Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


23.04.2018

1 Ann Neurol
1 Brain
2 J Neuroimmunol
2 Lancet Neurol
2 Mult Scler
1 Neurology
3 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. TANKOU SK, Regev K, Healy BC, Tjon E, et al
    A probiotic modulates the microbiome and immunity in multiple sclerosis.
    Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
    PubMed     Text format     Abstract available


    Brain

  2. VAN LANGELAAR J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, et al
    T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
    Brain. 2018 Apr 5. pii: 4961484. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  3. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Text format     Abstract available

  4. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Text format     Abstract available


    Lancet Neurol

  5. MARTIN R
    Understanding risk of PML through multiple sclerosis.
    Lancet Neurol. 2018;17:391-392.
    PubMed     Text format    

  6. MAJOR EO, Yousry TA, Clifford DB
    Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
    Lancet Neurol. 2018;17:467-480.
    PubMed     Text format     Abstract available


    Mult Scler

  7. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Text format     Abstract available

  8. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Text format     Abstract available


    Neurology

  9. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed     Text format    


    PLoS One

  10. CIURLEO R, Bonanno L, De Salvo S, Romeo L, et al
    Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study.
    PLoS One. 2018;13:e0196006.
    PubMed     Text format     Abstract available

  11. DE SANTIAGO L, Sanchez-Morla E, Blanco R, Miguel JM, et al
    Empirical mode decomposition processing to improve multifocal-visual-evoked-potential signal analysis in multiple sclerosis.
    PLoS One. 2018;13:e0194964.
    PubMed     Text format     Abstract available

  12. SANCHEZ-DALMAU B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, et al
    Predictors of vision impairment in Multiple Sclerosis.
    PLoS One. 2018;13:e0195856.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  13. AYRIGNAC X, Carra-Dalliere C, Labauge P
    Atypical inflammatory demyelinating lesions and atypical multiple sclerosis.
    Rev Neurol (Paris). 2018 Apr 16. pii: S0035-3787(17)30851.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: